Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Cortelezzi A, et al. Among authors: fabris s. Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220274 Clinical Trial.
Molecular analysis of 11q13 breakpoints in multiple myeloma.
Ronchetti D, Finelli P, Richelda R, Baldini L, Rocchi M, Viggiano L, Cuneo A, Bogni S, Fabris S, Lombardi L, Maiolo AT, Neri A. Ronchetti D, et al. Among authors: fabris s. Blood. 1999 Feb 15;93(4):1330-7. Blood. 1999. PMID: 9949176 Free article.
Transcriptional features of multiple myeloma patients with chromosome 1q gain.
Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, Basso D, Todoerti K, Lombardi L, Lambertenghi-Deliliers G, Neri A. Fabris S, et al. Leukemia. 2007 May;21(5):1113-6. doi: 10.1038/sj.leu.2404616. Epub 2007 Feb 22. Leukemia. 2007. PMID: 17315022 No abstract available.
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. Pruneri G, et al. Among authors: fabris s. Leuk Res. 2008 Oct;32(10):1628-32. doi: 10.1016/j.leukres.2008.02.002. Epub 2008 Mar 19. Leuk Res. 2008. PMID: 18355918 No abstract available.
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.
Morabito F, Cutrona G, Gentile M, Matis S, Todoerti K, Colombo M, Sonaglio C, Fabris S, Reverberi D, Megna M, Spriano M, Lucia E, Rossi E, Callea V, Mazzone C, Festini G, Zupo S, Molica S, Neri A, Ferrarini M. Morabito F, et al. Among authors: fabris s. Br J Haematol. 2009 Jun;146(1):44-53. doi: 10.1111/j.1365-2141.2009.07703.x. Epub 2009 May 6. Br J Haematol. 2009. PMID: 19438486 Free article.
220 results